Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Aug;21(4):595-9.
doi: 10.1016/j.pupt.2007.12.001. Epub 2008 Jan 29.

Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway

Affiliations
Review

Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway

Sophie Moreau-Marquis et al. Pulm Pharmacol Ther. 2008 Aug.

Abstract

The cystic fibrosis (CF) lung is chronically inflamed and infected by Pseudomonas aeruginosa, which is a major cause of morbidity and mortality in this genetic disease. Although aerosolization of Tobramycin into the airway of CF patients improves outcomes, the lungs of CF patients, even those receiving antibiotic therapy, are persistently colonized by P. aeruginosa. Recent studies suggest that the antibiotic resistance of P. aeruginosa in the CF lung is due to the formation of drug resistant biofilms, which are defined as communities of microbes associated with surfaces or interfaces, and whose growth is facilitated by thick and dehydrated mucus in the CF lung. In this review, we discuss some of the current models used to study biofilm formation in the context of biotic surfaces, such as airway cells, as well as the contribution of host-derived factors, including DNA, actin and mucus, to the formation of these microbial communities. We suggest that better in vitro models are required, both to understand the interaction of P. aeruginosa with the host airway, and as models to validate new therapeutics, whether targeted at bacteria or host.

PubMed Disclaimer

References

    1. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros. 2005;4 Suppl 2:3–5. - PubMed
    1. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15:194–222. - PMC - PubMed
    1. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE, Jr, Archibald LK, Gaynes RP, Tenover FC. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999;29:245–252. - PubMed
    1. Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, Repetto T, Doring G, de Martino M. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cyst Fibros. 2004;3:159–163. - PubMed
    1. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother. 1986;17:505–516. - PubMed

Publication types